Johnson & Johnson's single-dose vaccine works well against delta variant

Johnson & Johnson’s single-dose vaccine works well against delta variant

Johnson & Johnson’s Covid-19 vaccine works well against the delta variant and the immune response lasts for at least eight months, the company said Thursday, citing laboratory tests on the blood of vaccine recipients.

“Current data for the eight months studied so far shows that the Johnson & Johnson single injection COVID-19 vaccine generates a strong neutralizing antibody response that does not falter,” Dr Mathai Mammen, Global Head of Janssen Research & Development, Johnson & Johnson, said in a press release: “On the contrary, we are seeing improvement over time.”

The report comes as some people who received the single-dose vaccine questioned whether they would need a booster against the highly contagious mutated virus. The delta variant, which was first identified in India, now accounts for 25% of new Covid-19 cases in the United States and has been detected in all 50 states.

Comprehensive coverage of the coronavirus outbreak

Two doses of the Moderna and Pfizer-BioNTech mRNA vaccines have been shown to be highly effective against all known coronavirus variants, but it was not previously clear whether the Johnson & Johnson vaccine also protects against the delta mutation.

Some scientists and doctors have tweeted their concerns on social media about a June 14 scan from Public Health England which found that a single dose of AstraZeneca vaccine was less effective against symptomatic illnesses caused by the delta variant. , suggesting that people who had received the single dose Johnson & Johnson vaccine would need a booster of one of the mRNA vaccines.

Separate research in the UK found that mixing one dose of AstraZeneca and an mRNA vaccine produced a stronger immune response than two doses of AstraZeneca. The Johnson & Johnson and AstraZeneca vaccines are different, but share a similar technology, called a viral vector.

In a White House briefing Thursday, Dr Anthony Fauci said advice on vaccine recalls in the United States would be based on clinical data.

“We have to remember that the Johnson & Johnson vaccine is a very effective vaccine,” Fauci, director of the National Institute of Allergy and Infectious Diseases, said during the briefing.

More than 12 million doses of the Johnson & Johnson vaccine have been administered in the United States according to the Centers for Disease Control and Prevention.

The Associated Press contributed.